Drug Profile


Alternative Names: CS-3543; CX-3543; Itarnafloxin

Latest Information Update: 11 Mar 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cylene Pharmaceuticals
  • Class Antineoplastics; Fluoroquinolones; Small molecules
  • Mechanism of Action Apoptosis stimulants; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Neuroendocrine tumours

Most Recent Events

  • 06 Mar 2013 Quarfloxin licensed to TetraGene
  • 30 Jun 2010 Discontinued - Phase-II for Neuroendocrine tumours in USA (IV)
  • 03 Nov 2008 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top